NCCN临床实践指南_肾癌(2019.V4)英文版
61页1、NCCN org NCCN Guidelines for Patients available at www nccn org patients Version 4 2019 04 25 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Kidney Cancer Version 4 2019 April 25 2019 Continue Continue NCCN Guidelines Panel Disclosures Hematology oncology Patient advocacy Internal medicine Radi
2、otherapy Radiation oncology Medical oncology Urology Pathology Discussion writing committee member Robert J Motzer MD Chair Memorial Sloan Kettering Cancer Center Eric Jonasch MD Vice chair The University of Texas MD Anderson Cancer Center Neeraj Agarwal MD Huntsman Cancer Institute at the University of Utah Sam Bhayani MD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine William P Bro Kidney Cancer Association Sam S Chang MD Vanderbilt Ingram Cancer Ce
3、nter Toni K Choueiri MD Dana Farber Brigham and Women s Cancer Center Brian A Costello MD MS Mayo Clinic Cancer Center Ithaar H Derweesh MD UC San Diego Moores Cancer Center Rodney Ellis MD Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Mayer Fishman MD PhD Moffitt Cancer Center Thomas H Gallagher MD Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Saby George MD Roswell Park Comprehensive Cancer Center
4、 John L Gore MD MS Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Naomi Haas MD Abramson Cancer Center at the University of Pennsylvania Steven L Hancock MD Stanford Cancer Institute Michael R Harrison MD Duke Cancer Institute Won Kim MD UCSF Helen Diller Family Comprehensive Cancer Center Christos Kyriakopoulos MD University of Wisconsin Carbone Cancer Center Chad LaGrange MD Fred 17 1317 1324 lPatients with excellent performance status and normal organ function mSee Risk M
5、odels to Direct Treatment Predictors of Short Survival Used to Select Patients for Temsirolimus KID C nIn clear cell and non clear cell RCC with predominant sarcomatoid features gemcitabine doxorubicin category 2B and gemcitabine sunitinib category 2B have shown benefit KID 4 RELAPSE OR STAGE IV FIRST LINE THERAPY FOR CLEAR CELL HISTOLOGY Preferred regimensOther recommended regimensUseful under certain circumstances Favorable riskj Axitinib pembrolizumab Pazopanib Sunitinib Ipilimumab nivolumab
《NCCN临床实践指南_肾癌(2019.V4)英文版》由会员沧海****3分享,可在线阅读,更多相关《NCCN临床实践指南_肾癌(2019.V4)英文版》请在金锄头文库上搜索。
洁厕灵企业技术标准范例
发电企业热工设备检修规程
发电企业热控日常点检标准
发电企业汽机(含燃机)技术监督细则
发电企业电气设备保护及安全自动装置投退和定值变更管理标准
继电保护定值变更通知单
继电保护及安全自动装置投退审批表
电气保护定值更改申请单
化工企业粉尘涉爆企业整体安全风险等级评估方法
化工企业安全检查管理规程
电气安全管理规程范例
农业企业绿色食品大棚生菜生产操作规程
农业企业绿色食品桃园管理规程
农业企业绿色食品早春蕹菜生产操作规程
农业企业绿色食品大棚蚕豆促早栽培生产技术操作规程
农业企业绿色食品荠菜种植规程
农业企业绿色食品青椒种植规程
农业企业绿色食品筒篙种植规程
农业企业绿色食品油麦菜种植规程
农业企业绿色食品木耳菜种植规程
2023-05-11 11页
2022-09-05 10页
2022-08-18 10页
2022-08-18 6页
2022-08-18 7页
2022-08-18 3页
2022-08-18 5页
2022-08-18 9页
2022-08-18 7页
2022-08-18 4页